Advanced Prostate Cancer VL

Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans

Details
Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Read Mor...

Neoadjuvant Therapy for Men with High Risk Disease Prior to Prostatectomy - Mary-Ellen Taplin

Details
(Length of Conversation: 19 min) Mary-Ellen Taplin, MD, and Alicia Morgans, MD discuss the topic of neoadjuvant therapy for men with high-risk disease prior to surgery, specifically, prior to prostatectomy. Among the topics discussed include the importance of studying neoadjuvant chemotherapy and hormonal therapies in clinical trials before being used more broadly in everyday clinical practice, pa...

Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

Details
(Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...

The Past, Present, and Future Approaches to Prostate Biopsies - Baris Turkbey

Details
Dr. Baris Turkbey, Associate Research Physician of the Molecular Imaging Program at the National Cancer Institute, shares the past, present, and future approaches to prostate biopsies. Dr. Turkbey states that TRUS (Transrectal Ultrasound aka Systemic) biopsies have been the “standard of care” after PSA elevation for the past 25 years. However, prostate imaging is not always preceding biopsy. MRI p...

IRONMAN - A Better Understanding of the Variation in Care and Treatment - Daniel George

Details
(Length of Discussion: 17 min) Daniel George, MD and Director of GU Oncology talks with Alicia Morgans, MD about the IRONMAN initiative. The intent of the project was to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of a minimum of 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC...

Navigating the Adverse Effects of ADT - Neal Shore

Details
(Length of lecture - 19 minutes) Dr. Neal Shore addresses both the perception and evidence of side effect for patients on androgen deprivation therapy (ADT). There is a growing concern about ADT side effects now that it is being used more in non-metastatic prostate cancer, which is exposing men to ADT for longer periods of time. Several common adverse effects are known about ADT impacting multiple...

Biomarker Development in Advanced Prostate Cancer- Alicia Morgans

Details
(Length of Discussion: 25 min) Alicia Morgans, MD presents on the topic of biomarker development in advanced prostate cancer. In her presentation, Dr. Morgans discusses the difference between predictive and prognostic biomarkers and the importance of understanding the purpose of each. Also, Dr. Morgans identifies clinical biomarkers for men with mCRPC who are undergoing treatment with docetaxel. L...

Cognitive Function and Hormone Therapy in Advanced Prostate Cancer - Interview with Alicia Morgans

Details
(Length of Conversation: 7 min) Dr. Charles Ryan sits down with Dr. Alicia Morgans to discuss the study she's currently leading on Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer . This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. Spec...

Clinical Genomic Risk Classification - Daniel Spratt

Details
A Conversation on Clinical Genomic Risk Classification - Alicia Morgans and Daniel Spratt (Length of Conversation: 25 min) Daniel Spratt, MD discusses the clinical challenges to integrate genomic classifier results that report a continuous numerical risk of recurrence into treatment decisions for prostate cancer (PCa) and how his team aimed to develop a novel clinical-genomic risk system that can...

PRONOUNCE Trial: Cardiovascular Outcomes in Prostate Cancer - Susan Slovin

Details
(Length of Conversation: 19 min) Alicia Morgans, MD, MPH and Susan Slovin, MD, PhD, discuss the PRONOUNCE trial , which looks at cardiovascular outcomes in patients with prostate cancer. Dr. Slovin highlights the importance of considering cardiovascular disease as it is the second most common cause of death in men with prostate cancer. Literature in the past 15-20 years on the use a GNRH agonists...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe